抗体偶联药物相关角膜和眼表不良反应管理专家共识(2026)
抗体偶联药物(ADC)眼部不良反应主要累及角膜和眼表组织,影响患者生活质量和治疗依从性。中国民族卫生协会眼学科分会干眼研究型学组和中国康复医学会视觉康复专委会干眼康复学组联合相关领域专家,采用规范共识制订方法,针对8个临床问题形成共识性推荐意见,旨在为预防、诊断及治疗ADC角膜和眼表不良反应提供依据。
要点
- ADC眼部不良反应主要累及角膜和眼表组织,需规范化管理。
- 共识针对8个临床问题形成推荐意见,涵盖预防、诊断和治疗。
- 推荐多学科协作以提高ADC治疗获益并保障患者视觉健康。
核心结论
- 共识为ADC相关角膜和眼表不良反应的预防、诊断及治疗提供循证指导。
- 通过多学科协作提高ADC治疗获益,最大限度保障患者视觉健康和生活质量。
研究设计与样本
- 中国民族卫生协会眼学科分会干眼研究型学组和中国康复医学会视觉康复专委会干眼康复学组联合相关领域专家制订。
- 采用规范的共识制订方法,结合国内外最新研究结果和中国临床实践。
关键数值与推荐
- 针对与ADC角膜和眼表不良反应相关的8个临床问题形成共识性推荐意见。
临床怎么用
- 用于预防、诊断及治疗ADC角膜和眼表不良反应。
- 通过多学科协作管理ADC眼部不良反应,提高治疗获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antibody-drug conjugates (ADCs), as a novel class of targeted anticancer therapies, have demonstrated significantly enhanced efficacy. However, the associated ocular adverse events have emerged as a critical issue impacting patients' quality of life and treatment compliance. ADC-induced ocular adverse events primarily affect corneal and ocular surface tissues. With the recent approval of multiple ADC agents in China and the extensive ongoing clinical trials, standardized guidance for managing corneal and ocular surface adverse events is urgently needed. The Dry Eye Research Group of Ophthalmology Branch of Chinese National Health Association and the Dry Eye Rehabilitation Specialty of Vision Rehabilitation Committee of Chinese Rehabilitation Medicine Association, together with experts from relevant fields, have developed consensus recommendations based on integrated international research and Chinese clinical practice, using the standardized consensus development methods. These recommendations address eight clinical questions concerning corneal and ocular surface adverse events associated with ADCs, aiming to provide evidence-based guidance for the prevention, diagnosis, and management of ADC-related corneal and ocular surface adverse events. Through multidisciplinary collaboration, this consensus seeks to enhance therapeutic benefits of ADC treatment and maximize patients' visual health and quality of life. 抗体偶联药物(ADC)是一种新型靶向抗肿瘤药物,在显著提高疗效的同时,其眼部不良反应已成为影响患者生活质量和治疗依从性的重要问题。ADC眼部不良反应主要累及角膜和眼表组织,随着中国多种ADC应用于临床以及开展大量临床试验,眼部不良反应亟需进行规范化管理。中国民族卫生协会眼学科分会干眼研究型学组和中国康复医学会视觉康复专委会干眼康复学组联合相关领域的专家,结合国内外最新研究结果,采用规范的共识制订方法,针对与ADC角膜和眼表不良反应相关的8个临床问题,形成共识性推荐意见,旨在为预防、诊断及治疗ADC角膜和眼表不良反应提供依据,以多学科协作提高ADC治疗获益,从而最大限度保障患者的视觉健康和生活质量。.
引用
- [Chinese expert consensus on the management of corneal and ocular surface adverse events related to antibody-drug conjugates (2026)]. Zhonghua Yan Ke Za Zhi. 2026. PMID: 42855776. doi:10.3760/cma.j.cn112142-20260107-00010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。